Subscribe
shutterstock_1862407378_ralf_liebhold
Ralf Liebhold / Shutterstock.com
17 August 2021GenericsAlex Baldwin

Fed Circ upholds Teva cancer drug patents

The US Court of Appeals for the Federal Circuit has affirmed a Delaware court ruling upholding the validity of cancer drug patents owned by Teva Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Cephalon sues to protect cancer drug Treanda
19 March 2014   Teva-owned subsidiary Cephalon has sued Sun Pharma, claiming the Mumbai-based firm infringed a patent protecting its Treanda (bendamustine hydrochloride) product.
Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Cephalon sues to protect cancer drug Treanda
19 March 2014   Teva-owned subsidiary Cephalon has sued Sun Pharma, claiming the Mumbai-based firm infringed a patent protecting its Treanda (bendamustine hydrochloride) product.
Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.

More on this story

Americas
Cephalon sues to protect cancer drug Treanda
19 March 2014   Teva-owned subsidiary Cephalon has sued Sun Pharma, claiming the Mumbai-based firm infringed a patent protecting its Treanda (bendamustine hydrochloride) product.
Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner